Researchers at Virginia Tech’s Fralin Biomedical Research Institute at VTC have developed an encouraging three-pronged approach to treating glioblastoma, an aggressive brain cancer with an average survival time of approximately 15 months. Their findings published in Oncogenesis. “By using a combinational therapeutic... read full story
"By using a combinational therapeutic strategy, we've created a promising approach to combat chemoresistance in the most lethal brain cancer,"
